# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.sec.gov/Archives/edgar/data/1280776/000119380524000704/e663650_s3a-immunic.htm
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by ...
30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Com...
Brookline Capital analyst Tyler Bussian initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Ta...
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their conf...
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.51) by 5....